Company News: Page (1) of 1 - 05/15/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Solid Biosciences Announces Upcoming Preclinical Data Presentations

(May 15, 2018)

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held May 16-19, 2018 in Chicago.

Oral Presentations:

Poster Presentations:

About Solid Biosciences
Solid Biosciences†is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. Solidís lead clinical candidate for DMD is a novel adeno-associated viral (AAV) vector-mediated microdystrophin gene transfer called SGT-001. The Phase I/II clinical trial for SGT-001, IGNITE DMD, is currently on clinical hold.† For more information, please visit†www.solidbio.com.

Contact:
Solid Biosciences
Kate Niazi-Sai
+1 617-337-4680
[email protected]
[email protected]


Page: 1


Related Keywords:

-->

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved